Premium
African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies
Author(s) -
Fiala Mark A.
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32082
Subject(s) - medicine , daratumumab , multiple myeloma , population , lenalidomide , oncology , immune system , african american , immunology , monoclonal antibody , antibody , gerontology , ethnology , environmental health , history